Several nanotechnology-based drugs have been successfully developed and approved for clinical use. For instance, Doxil, a liposomal formulation of the anticancer drug doxorubicin, enhances the drug's efficacy while reducing its cardiotoxicity. Another example is Abraxane, a nanoparticle albumin-bound form of paclitaxel, used in the treatment of breast cancer.
